About Sierra Oncology (NASDAQ:DNAI)
Sierra Oncology, Inc., formerly ProNAi Therapeutics, Inc., is a clinical-stage drug development company. The Company's lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network. SRA737 is being investigated in approximately two Phase I clinical trials in patients with advanced cancer. Sierra Oncology is also advancing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase (Cdc7) kinase undergoing preclinical development. Sierra is building a range of pipeline of various oncology assets against targets at the edge of cancer biology. The Company's SRA737 and SRA141 target the DDR network, a scientifically approach with far-reaching potential across oncology. SRA141 is an orally available small molecule inhibitor of Cdc7.
Industry, Sector and Symbol:
- 50 Day Moving Avg: $1.48
- 200 Day Moving Avg: $1.72
- 52 Week Range: $1.32 - $10.37
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.33
- P/E Growth: 0.00
- Return on Equity: -35.50%
- Return on Assets: -33.93%
- Average Volume: 556,061 shs.
Frequently Asked Questions for Sierra Oncology (NASDAQ:DNAI)
What is Sierra Oncology's stock symbol?
Sierra Oncology trades on the NASDAQ under the ticker symbol "DNAI."
When will Sierra Oncology make its next earnings announcement?
Where is Sierra Oncology's stock going? Where will Sierra Oncology's stock price be in 2017?
1 analysts have issued twelve-month price targets for Sierra Oncology's shares. Their predictions range from $4.00 to $4.00. On average, they anticipate Sierra Oncology's share price to reach $4.00 in the next twelve months. View Analyst Ratings for Sierra Oncology.
Who are some of Sierra Oncology's key competitors?
Some companies that are related to Sierra Oncology include Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals Incorporated (VRTX), Kite Pharma (KITE), Exelixis (EXEL), bluebird bio (BLUE), BIOVERATIV INC (BIVV), TESARO (TSRO), Neurocrine Biosciences (NBIX), Juno Therapeutics (JUNO), Clovis Oncology (CLVS), BeiGene (BGNE), Agios Pharmaceuticals (AGIO), Sarepta Therapeutics (SRPT), AveXis (AVXS), Spark Therapeutics (ONCE), GW Pharmaceuticals PLC (GWPH) and Halozyme Therapeutics (HALO).
Who are Sierra Oncology's key executives?
Sierra Oncology's management team includes the folowing people:
- Donald R. Parfet, Independent Chairman of the Board
- Nicholas R. Glover Ph.D., President, Chief Executive Officer, Director
- Sukhi Jagpal, Chief Financial Officer
- Barbara Klencke M.D., Chief Development Officer
- Mark Kowalski M.D. Ph.D., Chief Medical Officer
- Angie J. You Ph.D., Chief Business & Strategy Officer and Head of Commercial
- Jeffrey H. Cooper, Independent Director
- Daniel Estes Ph.D., Independent Director
- Tran Nguyen, Independent Director
- Nicole Onetto M.D., Independent Director
When did Sierra Oncology IPO?
(DNAI) raised $100 million in an IPO on Thursday, July 16th 2015. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Jefferies and BofA Merrill Lynch served as the underwriters for the IPO and Wedbush PacGrow and SunTrust Robinson Humphrey were co-managers.
How do I buy Sierra Oncology stock?
Shares of Sierra Oncology can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sierra Oncology's stock price today?
MarketBeat Community Rating for Sierra Oncology (NASDAQ DNAI)MarketBeat's community ratings are surveys of what our community members think about Sierra Oncology and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Sierra Oncology stock can currently be purchased for approximately $1.56.
Consensus Ratings for Sierra Oncology (NASDAQ:DNAI) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Buy Rating|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$4.00 (156.41% upside)|Consensus Price Target History for Sierra Oncology (NASDAQ:DNAI)
Analysts' Ratings History for Sierra Oncology (NASDAQ:DNAI)
(Data available from 10/21/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
Earnings History for Sierra Oncology (NASDAQ:DNAI)Earnings History by Quarter for Sierra Oncology (NASDAQ DNAI)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Sierra Oncology (NASDAQ:DNAI)
Current Year EPS Consensus Estimate: $-1.55 EPS
Next Year EPS Consensus Estimate: $-1.17 EPS
Dividend History for Sierra Oncology (NASDAQ:DNAI)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Sierra Oncology (NASDAQ:DNAI)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Sierra Oncology (NASDAQ:DNAI)
Latest Headlines for Sierra Oncology (NASDAQ:DNAI)
|Sierra Oncology (SRRA) Presents At 2017 BIO Investor Forum - Slideshow|
seekingalpha.com - October 19 at 6:36 PM
|Sierra Oncology (SRRA) Updates on Next Generation DDR Therapeutics - Slideshow|
seekingalpha.com - September 20 at 6:46 PM
|Revisiting The ProNAi/Sierra Oncology Thesis 1 Year Later: Still Not Dead In The Water?|
seekingalpha.com - July 17 at 11:55 PM
|SIERRA ONCOLOGY, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Even|
biz.yahoo.com - January 11 at 5:16 PM
|FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against ProNAi Therapeutics, Inc. (DNAI) and Lead Plaintiff Deadline - January 9, 2017|
us.rd.yahoo.com - January 9 at 4:37 PM
|SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of a Class Action Lawsuit Against ProNAi Therapeutics, Inc. and a Lead Plaintiff Deadline of January 9, 2017 – DNAI|
us.rd.yahoo.com - January 4 at 5:49 PM
|INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Commencement of a Class Action Lawsuit Against ProNAi Therapeutics, Inc. and a Lead Plaintiff Deadline of January ...|
www.businesswire.com - December 30 at 1:42 AM
|SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against ProNAi Therapeutics, Inc. (DNAI) and Lead Plaintiff Deadline - January 9, 2017|
us.rd.yahoo.com - December 22 at 10:00 PM
|DNAI SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class ... - Business Wire (press release)|
www.businesswire.com - December 22 at 3:35 AM
|DNAI SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving ProNAi Therapeutics, Inc. and a Lead Plaintiff Deadline of ...|
www.businesswire.com - December 21 at 5:34 PM
|IMPORTANT SHAREHOLDER ALERT: Khang & Khang...|
www.benzinga.com - December 18 at 3:02 AM
Sierra Oncology (DNAI) Chart for Saturday, October, 21, 2017